Navigation Links
A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing
Date:5/16/2013

span>, namely A*STAR's Singapore Immunology Network (SIgN), DSO National Laboratories and Duke-NUS Graduate Medical School.Since early 2012, D3, which works hand in hand with Cytos and other local entities,has been leading the development of the H1N1 influenza vaccine project aiming to achieve proof-of-concept in humans. This Phase 1 clinical trial is being conducted at the SingHealth Investigational Medicine Unit and the Changi General Hospital Trials and Research unit in Singapore.

About Influenza Infection and Vaccination

According to the World Health Organisation, it is estimated that 10 to 20 percent of the world's population are infected during seasonal influenza epidemic, causing three to five million people to be seriously ill, and killing 250,000 to 500,000 each year[3]. One of the most effective ways to significantly reduce the incidence of death and serious illness from influenza is through vaccination. In the case of a pandemic, it is vital to be able to produce vaccines quickly and in large quantities to be able to vaccinate the majority of the population prior to the spreading of the pandemic influenza strain. The conventional way to produce influenza vaccine using chicken eggs has limited yields, is time consuming and sometimes constrained due to the toxicity of certain viral strains to birds (e.g. H5N1 bird flu virus). Growing the virus in cell cultures may get around strain toxicity, however the yields are also modest and the production cost are very high.

About the Influenza Vaccine Developed By A*STAR and Cytos

Cytos' proprietary technology used for this vaccine overcomes the short comings of conventional vaccines since all components can be produced recombinantly at high levels in E.coli. The vaccine encompasses on the one hand Cytos' clinically validated Qbeta VLP as an immunological carrier and on the other hand the globular domain
'/>"/>

SOURCE Cytos Biotechnology Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Tornado Medical Systems And A*STARs Institute Of Microelectronics Partner To Commercialise Nanospectrometers For Optical Coherence Tomography Applications
2. GlaxoSmithKline and A*STARs Institute of Chemical Engineering and Sciences to Develop new Medicines for Emerging Markets
3. Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
4. CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers
5. Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-IgE Vaccine
6. Industry Veteran Brings Sales Expertise to AlloSources Growing Distribution Network
7. Cardinal Health Brings Resolution to Litigation with DEA Settlement
8. CASiGEN Pharma Receives A World-wide Exclusive License From GIBH To Bring New Potential Diabetes Treatments To The Global Market
9. Clinical Site Services Is Bringing 3x More Patient Enrollment to the 48th Annual DIA Meeting
10. Vocollect Healthcare Systems And Prime Care Technologies Bring AccuNurse Key Performance Metrics To Long-Term Care Providers Via primeVIEW Digital Dashboard
11. Health Diagnostic Laboratory, Inc. (HDL, Inc.) Brings Advanced Testing to Capitol Hill, Discusses Health Care Cost Savings and Quality Improvement Potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very ... King as its new Chief Executive Officer.  Mark was ... which he has overseen the company,s four facilities in ... Costa Rica.  Mr. King joined Tegra Medical in 2012 with ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... 2011 Mylan Inc. (Nasdaq: MYL ) today announced ... which will resolve litigation related to Lipitor ® Tablets, 10 ... Atorvastatin Calcium Tablets. The terms of the agreement are confidential, and ... of Justice and the Federal Trade Commission. Lipitor had ...
... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today ... Johnson as Chief Executive Officer, effective January 31, 2011.  Mr. ... of directors. Mr. Johnson brings significant biotechnology business ... Vice President of Eli Lilly and Company and President of ...
Cached Medicine Technology:Mylan Announces LipitorĀ® Settlement Agreement 2Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 2Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 3Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 4
(Date:4/24/2014)... better to give than to receive at least if ... suggests. , The study found that 15- and 16-year-olds who ... to family members, are less likely to become depressed than ... keeping the money for themselves. , The researchers detail their ... Sciences . , The study focused on the ventral striatum, ...
(Date:4/24/2014)... Foundation has awarded LSU Health Sciences Center New ... grant in the amount of $295,635. The funding ... social and educational backgrounds, underrepresented in the sciences, ... project will provide students with training for 10 ... will be led by Principal Investigator Dr. Fern ...
(Date:4/23/2014)... unrelated donors was safe and effective in treating ... Clostridium difficile , according to a new pilot ... and available online. Known as fecal microbiota transplantation, ... a colonoscope or a nasogastric tube. The findings ... more readily available to patients. , A growing ...
(Date:4/23/2014)... M.D., scientific director at the National Institute of Arthritis ... the 2014 recipient of the Ross Prize in Molecular ... Molecular Medicine . The award will be given ... Sciences in Manhattan, followed by scientific presentations by Dr. ... the National Institutes of Health. , The award, which ...
(Date:4/23/2014)... developed a way to detect and measure cancer levels ... with tails of synthetic DNA., A team led by ... gold nanoparticles to target and bind to fragments of ... which can indicate the presence and stage of breast ... a cell can be determined by examining the specific ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... non-recurring event in 2007, net loss stable ... unless otherwise noted), BELLEVILLE, ON, Nov. 9 /PRNewswire-FirstCall/ ... Canadian,biopharmaceutical company, today announced financial results for the first,quarter ... "We are also focused on the successful completion ...
... HILL, N.C., Nov. 9 Pharmaceutical product teams,have ... of a new product. The problem is,launch teams ... to run,effectively and therefore only produce a sub-optimal ... executives agree that,collaborative behavior and cross-functional team work ...
... New Capital to Support Continued Advancement of Novel Technology and ... ... Anaptys Biosciences, Inc., a,privately-held therapeutic antibody product company, today announced ... led by Novo A/S.,Additional investors participating significantly in the round were ...
... FRANCISCO and CHICO, Calif., Nov. 8 State,Compensation ... health seminar,as part of State Fund,s Employer Education ... State Fund,s Back,Connection(TM). The three-hour seminar entitled "Watch ... shows employers how they,can involve the very people ...
... 8 InteKrin Therapeutics, Inc.,a privately-held clinical stage ... novel drugs for the treatment of,diabetes and cardio-metabolic ... joined the company as Chief Medical Officer. Dr. ... team and will be,responsible for the clinical development ...
... in 2008, OTTAWA, Canada, Nov. 8 ... press release is, http://www.naturalnutritioninc.com . Sports and ... Board: NNTN), http://www.naturalnutritioninc.com has recently expanded ... equipment to produce,sheeted protein and energy bars, ...
Cached Medicine News:Health News:Bioniche Reports Fiscal 2008 First Quarter 2Health News:Bioniche Reports Fiscal 2008 First Quarter 3Health News:Bioniche Reports Fiscal 2008 First Quarter 4Health News:Bioniche Reports Fiscal 2008 First Quarter 5Health News:Bioniche Reports Fiscal 2008 First Quarter 6Health News:Bioniche Reports Fiscal 2008 First Quarter 7Health News:Bioniche Reports Fiscal 2008 First Quarter 8Health News:Bioniche Reports Fiscal 2008 First Quarter 9Health News:Bioniche Reports Fiscal 2008 First Quarter 10Health News:Bioniche Reports Fiscal 2008 First Quarter 11Health News:Pharmaceutical Product Commercialization: Enabling Teams to Excel 2Health News:Pharmaceutical Product Commercialization: Enabling Teams to Excel 3Health News:Anaptys Biosciences Raises Over $33 Million in Series B Financing 2Health News:Anaptys Biosciences Raises Over $33 Million in Series B Financing 3Health News:Free Seminar Features State Fund's Back Connection(TM), November 14, in Chico 2Health News:Free Seminar Features State Fund's Back Connection(TM), November 14, in Chico 3Health News:InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer 2Health News:InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer 3Health News:Corrected & Replaced - Natural Nutrition Expands Revenue Capabilities with Newly Installed State of the Art Nutrition Bar Line 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: